
11 - 50 employees
Founded 2019
🏥 Healthcare
🏭 Manufacturing
🧬 Biotechnology
💰 $75M Series D - Spyglass Pharma on 2025-06
Healthcare • Manufacturing • Biotechnology
<SpyGlass Pharma, Inc. > SpyGlass Pharma, Inc. is a clinical-stage company developing the BIM-IOL System, a sustained drug-delivery intraocular lens designed to deliver long-acting glaucoma therapy at the time of cataract surgery. The technology integrates glaucoma treatment with a trusted surgical procedure to address gaps in adherence and chronic disease management, and the company is advancing the device through preclinical studies and clinical trials (first-in-human, Phase 1/2, and Phase 3).
Selected: 🆕 Date Added.
🕒 October 7
Vice President leading pricing, reimbursement, payer engagement, and commercialization access for SpyGlass Pharma’s ophthalmic drug-delivery therapies. Building the market access organization for Phase 3 and launch growth.
🏄 California – Remote
💵 $325k - $385k / year
💰 $75M Series D - Spyglass Pharma on 2025-06
⏰ Full Time
🔴 Lead
👔 Vice President
👻 Ghost score 0%
🕒 September 9
Leading Medical Affairs strategy and launch readiness for SpyGlass Pharma’s sustained ophthalmic drug delivery technology. Building field medical capabilities and driving evidence, KOL engagement, and scientific communications.
🏄 California – Remote
💵 $325k - $385k / year
💰 $75M Series D - Spyglass Pharma on 2025-06
⏰ Full Time
🔴 Lead
👔 Vice President
👻 Ghost score 0%
🕒 August 21
Medical Science Liaison supporting SpyGlass Pharma’s Phase 3 ophthalmic drug-delivery trials. Engaging investigators and sites across the U.S. to advance glaucoma treatment.
🇺🇸 United States – Remote
💵 $175k - $225k / year
💰 $75M Series D - Spyglass Pharma on 2025-06
⏰ Full Time
🟡 Mid-level
🟠 Senior
✨ Medical Science Liaison
👻 Ghost score 3%